• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 466195 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416951581 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416951581 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Acadia Pharmaceuticals on 3.0x Above-Average Volume (ACAD)

Published on Mon, 03/25/2013 - 13:09
By Robert Cotter

Shares of Acadia Pharmaceuticals are trading today in above average volume, with the share price rising 9.4% to $8.28. About 5.9 million shares have been traded today, as compared to the 30-day average volume of 1.9 million shares. Unusually high volume can signify a potential turning point or validate a breakout.

There is potential upside of 1.4% for shares of Acadia Pharmaceuticals based on a current price of $8.28 and an average consensus analyst price target of $8.40. The stock should find initial support at its 50-day moving average (MA) of $6.14 and further support at its 200-day MA of $3.42.

In the past 52 weeks, shares of Acadia Pharmaceuticals have traded between a low of $1.29 and a high of $8.81 and are now at $8.28, which is 542% above that low price. The 200-day and 50-day moving averages have moved 4.33% higher and 3.64% higher over the past week, respectively.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Shares of Ventas Rise Above Previous 52-...

Ventas (NYSE:VTR) traded today at a new 52-week high of $70.11. So far today approxima ...

Shares of Validus Holdings Rise to a New...

Shares of Validus Holdings (NYSE:VR) traded at a new 52-week high today of $41.42. So ...

Watch for Continued Gains in Shares of V...

Shares of VF Corp (NYSE:VFC) traded today at $74.38, breaking its 52-week high. This n ...

Shares of Valspar Have Risen Above Previ...

Valspar (NYSE:VAL) traded at a new 52-week high today of $87.59. Approximately 849,000 ...

Visa: The Winning Streak Continues (V)...

Visa (NYSE:V) traded today at a new 52-week high of $258.00. So far today approximatel ...

Union Pacific Looks to Continue to Trade...

Union Pacific (NYSE:UNP) traded today at a new 52-week high of $123.61. This new high ...

Shares of Textron Have Risen Above Previ...

Textron (NYSE:TXT) traded at a new 52-week high today of $44.47. This new high was rea ...

Shares of Take-Two Interactive Software ...

Take-Two Interactive Software (NASDAQ:TTWO) traded today at a new 52-week high of $28.0 ...